Meloxicam - Sedor Pharmaceuticals

Drug Profile

Meloxicam - Sedor Pharmaceuticals

Alternative Names: CE - Meloxicam

Latest Information Update: 21 Sep 2016

Price : $50

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer Sedor Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Amides; Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Small molecules; Thiazines; Thiazoles
  • Mechanism of Action Cyclo-oxygenase 2 inhibitors; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer pain; Postoperative pain

Most Recent Events

  • 08 Dec 2015 Preclinical trials in Cancer pain in USA (IM)
  • 08 Dec 2015 Preclinical trials in Cancer pain in USA (IV)
  • 08 Dec 2015 Captisol-enabled™ meloxicam licensed to RODES Pharmaceuticals in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top